Post-Marketing Surveillance,Annual Reports and Long Term Follow-Up

Report of the Joint Committee on Prescription Drug Use, 1980.

An Experiment in Early Post-Marketing Surveillance of Drugs, Task A, IMS America, Ltd. NTIS #PB288577-AS.

An Experiment in Early Post-Marketing Surveillance of Drugs, Task B, IMS America, Ltd. NTIS #80-PB139090.

An Experiment in Early Post-Marketing Surveillance of Drugs, Final Report, Task C, IMS America, Ltd. (No NTIS number available).

Slone D. Shapiro S. Miettinen O.S. : Case-control surveillance of serious illnesses attributable to ambulatory drug use. In, Epidemiological Evaluation of Drugs, Amsterdam: Elsevier/North-Holland Biomedical Press, pp. 59–70, 1977.

Cordero J.F. Oakley G.P. Greenberg F. : Is Bendectin a teratogen? JAMA 245:2307–2310, 1981.

Mitchell A.A. Rosenberg L. Shapiro S. : Birth defects related to Bendectin use in pregnancy. JAMA 245:2311–2314, 1981.

Hewitt D. Sanders B. Stewart A. : Oxford Survey of Childhood Cancers: Progress Report IV—Reliability of data reported by case and control mothers. Mon. Bull. Minist. Health 25:80, 1966.